{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:18:29Z","timestamp":1754151509352,"version":"3.41.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.7759\/cureus.88272","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T05:49:08Z","timestamp":1752904148000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness and Safety of Amlodipine, Telmisartan, and Chlorthalidone in Newly Diagnosed Hypertensive Indian Adults"],"prefix":"10.7759","author":[{"given":"Mohammed Danish","family":"Anwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2019.09.012","article-title":"Prevalence of hypertension among Indian adults: results from the great India blood pressure survey","volume":"71","author":"Ramakrishnan S","year":"2019","unstructured":"Ramakrishnan S, Zachariah G, Gupta K, et al.. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J. 2019, 71:309-13. 10.1016\/j.ihj.2019.09.012","journal-title":"Indian Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021, 398:957-80. 10.1016\/S0140-6736(21)01330-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Risk Factor Collaborators","year":"2018","unstructured":"GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1923-94. 10.1016\/S0140-6736(18)32225-6","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills KT","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020, 16:223-37. 10.1038\/s41581-019-0244-2","journal-title":"Nat Rev Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstr\u00f6m M","year":"2018","unstructured":"Brunstr\u00f6m M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018, 178:28-36. 10.1001\/jamainternmed.2017.6015","journal-title":"JAMA Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James PA","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al.. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014, 311:507-20. 10.1001\/jama.2013.284427","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2016.6.0409001052016","article-title":"Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension","volume":"6","author":"Raja M","year":"2016","unstructured":"Raja M, Shukla AK, Mehani R, Agnihotri A. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol. 2016, 6:388-93. 10.5455\/njppp.2016.6.0409001052016","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32317-7","article-title":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis","volume":"394","author":"Suchard MA","year":"2019","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, et al.. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019, 394:1816-26. 10.1016\/S0140-6736(19)32317-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019)","volume":"34","author":"Shah SN","year":"2020","unstructured":"Shah SN, Munjal YP, Kamath SA, et al.. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020, 34:745-58. 10.1038\/s41371-020-0349-x","journal-title":"J Hum Hypertens"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2017.v10i2.15854","article-title":"Comparison of efficacy and adverse drug reactions of monotherapy versus combination therapy of antihypertensives among diabetic hypertensive patients in a tertiary care hospital","volume":"10","author":"Aulose RM","year":"2017","unstructured":"Aulose RM, Bairy LK, Prabhu MM, Eesha BR. Comparison of efficacy and adverse drug reactions of monotherapy versus combination therapy of antihypertensives among diabetic hypertensive patients in a tertiary care hospital. Asian J Pharm Clin Res. 2017, 10:385-91. 10.22159\/ajpcr.2017.v10i2.15854","journal-title":"Asian J Pharm Clin Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/9352.4500","article-title":"Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension","volume":"8","author":"Goyal J","year":"2014","unstructured":"Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014, 8:HC08-11. 10.7860\/JCDR\/2014\/9352.4500","journal-title":"J Clin Diagn Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger T","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al.. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020, 75:1334-57. 10.1161\/HYPERTENSIONAHA.120.15026","journal-title":"Hypertension"},{"key":"ref13","unstructured":"WHO guidelines approved by the Guidelines Review Committee. Guideline for the pharmacological treatment of hypertension in adults. (2021). Accessed. February 10, 2025: https:\/\/www.who.int\/publications\/i\/item\/9789240033986."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams B","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al.. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018, 39:3021-104. 10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"ref15","article-title":"JNC 8: what\u2019s covered, what\u2019s not, and what else to consider","volume":"63","author":"Mahvan TD","year":"2014","unstructured":"Mahvan TD, Mlodinow SG. JNC 8: what\u2019s covered, what\u2019s not, and what else to consider. J Fam Pract. 2014, 63:574-84.","journal-title":"J Fam Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004071","article-title":"Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement","volume":"95","author":"Paz MA","year":"2016","unstructured":"Paz MA, de-La-Sierra A, S\u00e1ez M, et al.. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore). 2016, 95:e4071. 10.1097\/MD.0000000000004071","journal-title":"Medicine (Baltimore)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.17511\/ijmrr.2016.i09.30","article-title":"Comparative study of telmisartan and amlodipine to assess the effect on blood pressure, lipid profile and blood glucose level in Indian hypertensive patients","volume":"4","author":"Tripathi N","year":"2016","unstructured":"Tripathi N, Bohara S, Singh RR, Kumar A, Uraiya D, Dhoan P. Comparative study of telmisartan and amlodipine to assess the effect on blood pressure, lipid profile and blood glucose level in Indian hypertensive patients. Int J Med Res Rev. 2016, 4:1693-701. 10.17511\/ijmrr.2016.i09.30","journal-title":"Int J Med Res Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3126\/kumj.v13i3.16806","article-title":"Efficacy of different antihypertensive drugs among newly diagnosed hypertensive patient in Dhulikhel Hospital","volume":"13","author":"Humagain S","year":"2015","unstructured":"Humagain S, Koju R. Efficacy of different antihypertensive drugs among newly diagnosed hypertensive patient in Dhulikhel Hospital. Kathmandu Univ Med J (KUMJ). 2015, 13:212-5. 10.3126\/kumj.v13i3.16806","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon S","year":"1990","unstructured":"MacMahon S, Peto R, Cutler J, et al.. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990, 335:765-74. 10.1016\/0140-6736(90)90878-9","journal-title":"Lancet"},{"key":"ref20","article-title":"Comparison of safety and efficacy of different class of anti-hypertensive drugs prescribed in patients with hypertension","volume":"12","author":"Suthar J","year":"2019","unstructured":"Suthar J, Patel A, Shelat B. Comparison of safety and efficacy of different class of anti-hypertensive drugs prescribed in patients with hypertension. Indian J Pharm Pract. 2019, 12:256-61.","journal-title":"Indian J Pharm Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14 Suppl 1","author":"Israili ZH","year":"2000","unstructured":"Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000, 14 Suppl 1:S73-86. 10.1038\/sj.jhh.1000991","journal-title":"J Hum Hypertens"},{"key":"ref22","article-title":"New guidelines for the treatment of hypertension: reemergence of chlorthalidone in the treatment of hypertension","volume":"4","author":"Jangamani R","year":"2018","unstructured":"Jangamani R, Sundar S. New guidelines for the treatment of hypertension: reemergence of chlorthalidone in the treatment of hypertension. Hypertens. 2018, 4:127-31.","journal-title":"Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288:2981-97. 10.1001\/jama.288.23.2981","journal-title":"JAMA"},{"key":"ref24","article-title":"First among equals: a comparative study of the effect of hydrochlorothiazide and chlorthalidone on recently diagnosed hypertensives","volume":"8","author":"Kumar B","year":"2015","unstructured":"Kumar B, Kaur S, Manzoor S, Singh HJ. First among equals: a comparative study of the effect of hydrochlorothiazide and chlorthalidone on recently diagnosed hypertensives. Asian J Pharm Clin Res. 2015, 8:195-8.","journal-title":"Asian J Pharm Clin Res"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.2165\/00044011-199700131-00011","article-title":"Effect of amlodipine on insulin secretion, glucose, lipid profile and urinary albumin excretion in patients with mild hypertension and non-insulin-dependent diabetes","volume":"13","author":"Faglia E","year":"1997","unstructured":"Faglia E, Favales F, Quarantiello A, et al.. Effect of amlodipine on insulin secretion, glucose, lipid profile and urinary albumin excretion in patients with mild hypertension and non-insulin-dependent diabetes. Clin Drug Invest. 1997, 13:56-66.","journal-title":"Clin Drug Invest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-2-199501150-00010","article-title":"Effects of antihypertensive therapy on serum lipids","volume":"122","author":"Kasiske BL","year":"1995","unstructured":"Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995, 122:133-41. 10.7326\/0003-4819-122-2-199501150-00010","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(01)02224-5","article-title":"Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension","volume":"15","author":"Grimm RH Jr","year":"2002","unstructured":"Grimm RH Jr, Black H, Rowen R, et al.. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. Am J Hypertens. 2002, 15:31-6. 10.1016\/s0895-7061(01)02224-5","journal-title":"Am J Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S265399","article-title":"Anti-diabetic effect of telmisartan through its partial PPAR\u03b3-agonistic activity","volume":"13","author":"Ayza MA","year":"2020","unstructured":"Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF. Anti-diabetic effect of telmisartan through its partial PPAR\u03b3-agonistic activity. Diabetes Metab Syndr Obes. 2020, 13:3627-35. 10.2147\/DMSO.S265399","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref29","article-title":"Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: a randomized, double blind, 12 week trial","volume":"5","author":"Dakhale G","year":"2015","unstructured":"Dakhale G, Salve A, Hardas M, Mahatme M, Hiware S, Shinde A. Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: a randomized, double blind, 12 week trial. Int J Pharmacol Res. 2015, 5:80-5.","journal-title":"Int J Pharmacol Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.11.008","article-title":"Metabolic actions of angiotensin receptor antagonists: PPAR-\u03b3 agonist actions or a class effect?","volume":"7","author":"Ernsberger P","year":"2007","unstructured":"Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-\u03b3 agonist actions or a class effect?. Curr Opin Pharmacol. 2007, 7:140-5. 10.1016\/j.coph.2006.11.008","journal-title":"Curr Opin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355375-comparative-effectiveness-and-safety-of-amlodipine-telmisartan-and-chlorthalidone-in-newly-diagnosed-hypertensive-indian-adults","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T05:49:13Z","timestamp":1752904153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355375-comparative-effectiveness-and-safety-of-amlodipine-telmisartan-and-chlorthalidone-in-newly-diagnosed-hypertensive-indian-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.88272","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}